Assessment of Consensus-Based Pharmacological Therapies in Irritable Bowel Syndrome

The irritable bowel syndrome (IBS) is a symptom-based gastrointestinal (GI) disease with the presence of symptoms such as abdominal pain and abnormal intestinal activities. It is a frequent GI problem encountered by physicians. The purpose of this paper was to review and assess some of the current and emerging pharmacological therapies for this syndrome. In the present study, data on the IBS were principally collected via Google Scholar and PubMed, followed by articles in journals and libraries. The pathophysiology of the IBS has yet to be fully elucidated. Global medical attempts, including pharmacological therapy and herbal remedies, aim at curing and/or subsiding pain, flatulence, diarrhea, and constipation. There is a need for new drugs in the setting of pharmacological therapy for the IBS. A new medical approach should include both novel and traditional drugs in order to reach to a desirable outcome for patients and improve their quality of life.